ResearchMoz

LY2189265 (Type 2 Diabetes) Analysis and Forecasts to 2020

GlobalData
Published Date » 2012-01-31
No. Of Pages » 42

GlobalDatas pharmaceuticals report, LY2189265 (Type 2 Diabetes) Analysis and Forecasts to 2020 provides LY2189265 sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2014-2020). The report also includes information on Type 2 Diabetes market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of LY2189265 including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of LY2189265 including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2014-2020 for LY2189265 in each of the seven major markets
Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Content

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 4

2 Introduction 5
2.1 Diabetes 5
2.2 Epidemiology 5
2.2.1 Prevalence 5
2.2.2 Mortality 7
2.3 Etiology and Risk Factors 9
2.3.1 Obesity 9
2.3.2 Sedentary Lifestyle 9
2.3.3 Family History and Genetics 9
2.3.4 Ethnicity 9
2.3.5 Old Age 9
2.4 Economic Impact of Diabetes 9
2.5 GlobalData Report Guidance 11

3 Type 2 Diabetes: Market Characterization 12
3.1 Type 2 Diabetes Market 12
3.2 Type 2 Diabetes Market Forecasts 13
3.3 Type 2 Diabetes Market: Drivers and Restraints 14
3.3.1 Drivers 14
3.3.2 Restraints 15

4 Classification of Diabetes 16
4.1 Types of Diabetes 16
4.1.1 Type 1 Diabetes 16
4.1.2 Type 2 Diabetes 16
4.1.3 Gestational Diabetes 16
4.2 Diabetes Complications 16
4.2.1 Cardiovascular Disease 16
4.2.2 Nephropathy 17
4.2.3 Neuropathy 17
4.2.4 Amputation 17
4.2.5 Retinopathy 17

5 Evolution of Anti-Diabetic Treatments 18

6 Medications 19
6.1 Insulin 19
6.2 Oral Medications 19
6.2.1 Sulfonylureas (SUR) 19
6.2.2 Biguanides (BGDs) 20
6.2.3 Alpha-Glucosidase Inhibitors (AGI) 21
6.2.4 Meglitinides 21
6.2.5 Thiazolidinediones (TZDs) 22
6.2.6 Dipeptidyl Peptidase IV (DPP- 4) Inhibitors 23
6.2.7 Oral Combination Therapy 23
6.3 Other Injectionable Medications 24
6.3.1 Pramlintide 24
6.3.2 Exenatide 24
6.4 Market Share as per Classes in Type 2 Diabetes 24

7 LY2189265 25
7.1 Introduction 25
7.2 Mechanism of Action 25
7.3 Clinical Studies 25
7.3.1 Phase II 25
7.3.2 Phase III 25
7.4 Factors Affecting Sales of LY2189265 26
7.4.1 Once Weekly Dosage 26
7.4.2 Competition from Januvia 26
7.4.3 Approval of Bydureon 26
7.5 Drug Evaluation 26
7.5.1 Drug Risk Benefit Score 26
7.5.2 Intensity of Competition 27
7.6 Sales Forecasts 27
7.6.1 Target Patient Pool for LY2189265 27
7.6.2 Dosing 27
7.6.3 Market Penetration 28
7.6.4 Annual Cost of Therapy 29
7.6.5 Sales Projections of LY2189265 30

8 Diabetes Market: Appendix 39
8.1 Market Definitions 39
8.2 List of Abberiviations 39
8.3 Research Methodology 39
8.3.1 Coverage 39
8.3.2 Secondary Research 40
8.3.3 Forecasting 40
8.3.4 Number of patients approved to take the drug 40
8.3.5 Net Penetration of Drug 41
8.3.6 Net Annual Dosing 41
8.3.7 Annual Cost of Therapy 41
8.4 Drug Sales Estimates Model 41
8.5 Contact Us 41
8.6 Disclaimer 41
8.7 Sources 42

List of Tables


Table 1: Diabetes, World, Prevalence Estimates for the age group 20-79 years (million), 2000-2030 5
Table 2: Diabetes, Top 10 Countries, by Prevalence (million), 2010 and 2030 7
Table 3: Diabetes, Top 10 Countries, Highest Health Expenditures ($bn), 2010 10
Table 4: Type 2 Diabetes, World, Major Marketed Drugs by Sales ($m), 2010 12
Table 5: Type 2 Diabetes, World, Major Pipeline Products in Phase III Clinical Trials 13
Table 6: Diabetes, Worldwide, Prevalence Estimates, 2010 and 2030 14
Table 7: Overweight*, Global, Prevalence Estimates in Males Aged 15 and above (%), 2005 15
Table 8: Diabetes Drugs Evolution 18
Table 9: Drug Risk Benefit Score of LY2189265 26
Table 10: Estimated Annual Cost of Therapy of LY189265, 2014 29
Table 11: LY2189265, Type 2 Diabetes, Global, Sales Forecasts ($m), 20142020 30
Table 12: LY2189265, Type 2 Diabetes, The US, Sales Forecasts ($m), 20142020 31
Table 13: LY2189265, Type 2 Diabetes, The UK, Sales Forecasts ($m), 20142020 32
Table 14: LY2189265, Type 2 Diabetes, France, Sales Forecasts ($m), 20142020 33
Table 15: LY2189265, Type 2 Diabetes, Germany, Sales Forecasts ($m), 20142020 34
Table 16: LY2189265, Type 2 Diabetes, Italy, Sales Forecasts ($m), 20142020 35
Table 17: LY2189265, Type 2 Diabetes, Spain, Sales Forecasts ($m), 20142020 36
Table 18: LY2189265, Type 2 Diabetes, Japan, Sales Forecasts ($m), 20162020 37

List of Figures


Figure 1: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2010 6
Figure 2: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2030 6
Figure 3: Diabetes, World, Mortality, 2010 7
Figure 4: Top 10 Causes of Mortality, Worldwide, 2008 8
Figure 5: Type 2 Diabetes, Global, Market Size Forecasts ($bn), 20102020 13
Figure 6: Mechanism of Action of Sulfonylureas 19
Figure 7: Mechanism of Action of Biguanide, Thiazolidinediones, Alpha-Glucosidase Inhibitors 20
Figure 8: Mechanism of Action of Metformin and Alpha-Glucosidase Inhibitors 21
Figure 9: Mechanism of Action of Thiazolidinediones 22
Figure 10: Mechanism of Action of DPP IV Inhibitors 23
Figure 11: Type 2 Diabetes, Global, Branded Market Share by Value, By Class (%), 2010 24
Figure 12: LY2189265, Type 2 Diabetes, Global, Sales Forecasts ($m), 20142020 30
Figure 13: LY2189265, Type 2 Diabetes, The US, Sales Forecasts ($m), 20142020 31
Figure 14: LY2189265, Type 2 Diabetes, The UK, Sales Forecasts ($m), 20142020 32
Figure 15: LY2189265, Type 2 Diabetes, France, Sales Forecasts ($m), 20142020 33
Figure 16: LY2189265, Type 2 Diabetes, Germany, Sales Forecasts ($m), 20142020 34
Figure 17: LY2189265, Type 2 Diabetes, Italy, Sales Forecasts ($m), 20122020 35
Figure 18: LY2189265, Type 2 Diabetes, Spain, Sales Forecasts ($m), 20142020 36
Figure 19: LY2189265, Type 2 Diabetes, Japan, Sales Forecasts ($m), 20162020 37
Figure 20: LY2189265, Type 2 Diabetes, Global, Sales Distribution (%), 2020 38
Figure 21: Patients Approved for the Drug 40

Upcoming Reports:

Poland: market of vitrifiable enamels and glazes
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the vitrifiable enamels and glazes market in Poland and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the vitrifiable enamels and glazes market in Poland, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report...
Trauma Devices Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
The physical injuries such as burns, dislocations, fractures, sprains and strains caused by any external source are termed as trauma. According to the CDC, trauma is defined as “an injury or wound to a living body caused by the application of external force or violence”. To treat this trauma various procedures are available and their use is determined by the severity of injury. Trauma devices are one of the key treatment methods for the same.  The trauma devices can be categorized in two segments namely external fixation devices and internal fixation devices....
Oral Care Products Market - Global Industry Size, Market Share, Trends, Analysis, And Forecasts 2012 - 2018
By - Transparency Market Research
The oral care product market is growing rapidly due to technological advancements and introduction of fresh products in the market. Dentifrice and toothbrush are mainly responsible for the primary growth of this market. Rise in consciousness about maintaining oral care is likely to increase the growth rate in the near future. There are a variety of oral care products available in market manufactured by different companies.  This research report analyzes the oral care product market on the basis of its segments and four major geographies. This research study...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.com
Select License type:

Share this report

Related News

Private Schools Have Higher Male Teaching Staff Than State Schools: Report
Oct 22, 2014  
Private and state education has always been a matter of debate across the UK. A recent study has shown that when it comes to teaching employment options, the difference between state-run and private education in terms of gender balance is absolutely clear.  A report by the Independent Schools Council (ISC) shows that while women dominate both the education medium, the number of...
Abbots First Australian Renewable Energy Deal Rejected
Oct 22, 2014  
The Abbot government’s initial deal for a renewable energy plan has been immediately rejected by the clean energy industry and Labor. The negotiations are about a bipartisan agreement regarding the future of the Australian renewable energy target. The Labor party rejected the first plan as being a job-killer before it was even announced. The plan, they said, would protect solar...
Chemical Production in Europe Flatlines in First Seven Months of 2014
Oct 21, 2014  
The recently published report by European Chemical Industry Council (Cefic) shows overall chemical production in Europe has flatlined in first seven months of this year. Though the initial four months showed a positive trend, the production volumes dropped in July 2014 and in the following months as well. The contraction in output in the three consecutive months has nullified the upward trend...
Actavis to Compete for Omega Pharma
Oct 20, 2014  
Actavic Plc has declared that it will become one of the bidders for the Omega Pharma NV deal, as the United States based drug maker keeps searching for more takeovers. Actavis will be competing against Boehringer Ingelheim GmbH, Sanofi and Perrigi Co. for Omega Pharma. Actavis places themselves as a potential suitor along with quarry in a multitude of potential pharma combinations....
Sale of iPhone Fuels UKs s
Oct 20, 2014  
With the sale of Apple Inc.’s latest smartphone, consumer expenditure on electronics has registered a three-year high this September. The new iPhone 6 and iPhone 6 Plus were launched in the U.K. on September 19 and buyers from across the country raced to purchase the newest smartphone. Both these smartphones are so far the fastest selling Apple products with a sale of over 10 million...